RT Journal Article
SR Electronic
T1 A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosing for tuberculosis treatment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.17.21249995
DO 10.1101/2021.01.17.21249995
A1 Verma, Renu
A1 Patil, Sunita
A1 Zhang, Nan
A1 Figueira Moreira, Flora Martinez
A1 Vitorio, Marize Teixeira
A1 da Silva Santos, Andrea
A1 Wallace, Ellen
A1 Gnanashanmugam, Devasena
A1 Persing, David
A1 Savic, Rada
A1 Croda, Julio
A1 Andrews, Jason R.
YR 2021
UL http://medrxiv.org/content/early/2021/01/20/2021.01.17.21249995.abstract
AB Treatment of tuberculosis involves use of standardized weight-based doses of antibiotics, but there remains a substantial incidence of toxicities, inadequate treatment response, and relapse, in part due to variable drug levels achieved. Single nucleotide polymorphisms (SNPs) in the N-acetyltransferase-2 (NAT2) gene explain 88% of interindividual pharmacokinetic variability of isoniazid, one of the two most important antitubercular antibiotics. A major obstacle to implementing pharmacogenomic guided dosing is the lack of a point-of-care assay. We trained an acetylation genotype classification model from a global dataset of 5,738 genomes, which achieved 100% accuracy in out-of-sample prediction on unphased SNPs from 2,823 samples using 5 SNPs. On a clinical dataset of 49 patients with tuberculosis, we found that a 5 SNP assay accurately predicted acetylation ratios and isoniazid clearance. We then developed a cartridge-based molecular assay for the 5 SNPs on the GeneXpert platform, which enabled accurate classification of allele patterns directly from as little as 25 ul of whole blood. An automated pharmacogenomic assay on a platform widely used globally for tuberculosis diagnosis could enable improved dosing of isoniazid, averting toxicities and improving treatment outcomes.Competing Interest StatementJRA and RV are named co-inventors on a provisional patent (Application number 62/991,477) for a NAT2 pharmacogenomic assayClinical TrialN/AFunding StatementFleXcartridges and technical support for their use were provided by Cepheid. This study was supported by the Institute for Immunity, Transplantation, and Infection and the Department of Medicine at Stanford University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The clinical study was approved by the institutional review boards of the Stanford University School of Medicine and Federal University of Grande Dourados (IRB# 33005)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the findings of this manuscript are available in the Supplementary Information files or from the corresponding author upon request.